Not available
Quote | AC Immune SA (NASDAQ:ACIU)
Last: | $3.91 |
---|---|
Change Percent: | -1.02% |
Open: | $3.95 |
Close: | $3.91 |
High: | $4.11 |
Low: | $3.83 |
Volume: | 216,517 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | AC Immune SA (NASDAQ:ACIU)
2024-07-26 15:10:34 ET Summary AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI...
2024-07-25 12:51:47 ET More on AC Immune AC Immune rockets 47% on Alzheimer's therapy deal with Takeda Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune Read the full article ...
Message Board Posts | AC Immune SA (NASDAQ:ACIU)
Subject | By | Source | When |
---|---|---|---|
WOOHOOOOOO WOOHOOOOOO awesome break out | weedtrader420 | investorshub | 06/27/2023 5:01:28 PM |
WOOHOOOOOO WOOHOOOOOO | weedtrader420 | investorshub | 06/27/2023 2:59:02 PM |
FDA fast track | weedtrader420 | investorshub | 06/27/2023 12:24:08 PM |
$ACIU$ | weedtrader420 | investorshub | 06/27/2023 12:21:23 PM |
ACIOU AND SOMETIMES Y | TheFinalCD | investorshub | 06/27/2023 11:20:28 AM |
News, Short Squeeze, Breakout and More Instantly...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner ...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...